- KALBITOR net sales increased to $9.2 million, a 14% increase over first quarter 2012;
- 518 patients have treated with KALBITOR, up 12% from the previous quarter;
- Operating cash burn in the second quarter was reduced to $7.0 million, down from $8.5 million in the prior quarter; and
- Cash, cash equivalents and investments at June 30, 2012 totaled approximately $38.6 million.
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the second quarter ended June 30, 2012. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers – the KALBITOR ® (ecallantide) business and angioedema franchise, as well as the Licensing and Funded Research Program (LFRP). Highlights of the second quarter 2012 include: